Abstract
High performance liquid chromatography was coupled with UV detection for simultaneous quantification of lopinavir (LPV) and ritonavir (RTV) in human plasma. This assay was sensitive, accurate and simple, and only used 200 μL of plasma sample. Samples were liquid-liquid extracted, and diazepam was used as an internal standard. The chromatographic separation was achieved on a C18 reversed-phase analytic column with a mobile phase of acetonitrile-sodium dihydrogen phosphate buffer (10 mmol L−1, pH 4.80) (60:40, v/v). UV detection was conducted at 205 nm and the column oven was set at 40°C. Calibration curves were constructed between 0.5–20 μg mL−1 for LPV and 0.05–5 μg mL−1 for RTV. The relative standard deviations were 2.16%–3.20% for LPV and 2.12%–2.60% for RTV for intra-day analysis, and 2.34%–4.04% for LPV and 0.31%–4.94% for RTV for inter-day analysis. The accuracy was within 100%±10%. The mean extraction recoveries were 79.17%, 52.26% and 91.35% for RTV, LPV and diazepam, respectively. This method was successfully applied to human plasma samples from patients orally administered a salvage regimen of lopinavir-ritonavir tablets.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother, 2008, 9: 2363–2375
Cvetkovic R S, Goa K L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs, 2003, 63: 769–802
Kaplan S S, Hicks C B. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother, 2005, 6: 1573–1585
Manosuthi W, Kiertiburanakul S, Amornnimit W, et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther, 2009, 6: 30
Josephson F, Andersson M C, Flamholc L, et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur J Clin Pharmacol, 2010, 66: 349–357
Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 2003, 47: 350–359
DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-nfected Adults and Adolescents. 2009. http://AIDSinfonihgov
Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ ritonavir-containing regimens. J Acquir Immune Defic Syndr, 2003, 33: 594–600
Hammer S M, Eron J J Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama, 2008, 300: 555–570
Thompson M A, Aberg J A, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Jama, 2010, 304: 321–333
la Porte C J, Colbers E P, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother, 2004, 48: 1553–1560
Sham H L, Kempf D J, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother, 1998, 42: 3218–3224
D’Avolio A, Siccardi M, Sciandra M, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 859: 234–240
Colombo S, Guignard N, Marzolini C, et al. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 810: 25–34
Droste J A, Verweij-Van Wissen C P, Burger D M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit, 2003, 25: 393–399
Hirano A, Takahashi M, Kinoshita E, et al. High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma. Biol Pharm Bull, 2010, 33: 1426–1429
Proust V, Toth K, Hulin A, et al. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B Biomed Sci Appl, 2000, 742: 453–458
Marzolini C, Beguin A, Telenti A, et al. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 774: 127–140
Ray J, Pang E, Carey D. Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 775: 225–230
Takahashi M, Yoshida M, Oki T, et al. Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. Biol Pharm Bull, 2005, 28: 1286–1290
Usami Y, Oki T, Nakai M, et al. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. Chem Pharm Bull, 2003, 51: 715–718
Elens L, Veriter S, Di Fazio V, et al. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clin Chem, 2009, 55: 170–174
Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol, 2006, 195: 296–301
Remmel R P, Kawle S P, Weller D, et al. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem, 2000, 46: 73–81
Solas C, Poizot-Martin I, Drogoul M P, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol, 2004, 57: 436–440
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kou, H., Ye, M., Fu, Q. et al. Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection. Sci. China Life Sci. 55, 321–327 (2012). https://doi.org/10.1007/s11427-012-4303-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-012-4303-1